Dear Novavax (NVAX) fans, mark your calendars for June 7th

Shares of Novavax (NASDAQ:NVAX) equities are in the spotlight today after a positive development from the United States Food and Drug Administration (FDA). Specifically, the FDA announced that its advisory committee will meet on June 7 to review the emergency use authorization (EUA) submission for its Covid-19 vaccine. The experimental vaccine, NVX-CoV2373, has already been authorized by the UK, Europe and the World Health Organization (WHO).

Source: Vladimka Production / Shutterstock.com

This morning, NVAX stock was up 14% this morning before shedding about 10% of its gains. However, the company has also lost over 60% of its value since the start of 2022.

Here’s what investors need to know about NVAX stocks going forward.

NVAX stock: FDA to discuss vaccine on June 7

Earlier this month, an FDA official called the vaccine’s review process “incredibly complex.” However, the EUA submission has been in the hands of the FDA for several months now, so a specific review date is great news.

Novavax’s vaccine can be stored in a normal refrigerator for up to six months, making it ideal for international shipping. According to the results of a phase 3 clinical trial in December, NVX-CoV2373 is also 90.4% effective against infections and 100% effective against moderate to severe disease. The trial was conducted among 29,949 adults in the United States and Mexico.

After two doses of the vaccine, anti-spike antibody levels against the omicron variant increased 61.1-fold. After a third dose, six months after the second, antibody levels against omicron increased 73.5 times. Additionally, no moderate or severe illnesses were reported in participants who received the vaccine.

Last year the Serum Institute of India entered into an agreement with Novavax to produce the vaccine under the Covovax name. Novavax also began clinical studies for an omicron-specific vaccine last January.

Who bets big on Novavax?

Tracking institutional ownership is important because these large funds provide liquidity and support for stocks. Analyzing which funds own Novavax is also important because said funds are likely betting on the success of its vaccine. During the fourth trimester, 415 funds declared owner of the company, a decrease of 16 funds compared to the previous quarter. Meanwhile, the institutional put/call ratio stands at 1.82, down from 1.32 in the prior quarter. This means that the funds hold more put options against Novavax than call options. The high put/call ratio does not add up well for the company.

So, with that in mind, let’s take a look at NVAX’s top five shareholders:

  1. vanguard group: 6.89 million shares or 9.04% ownership.
  2. black rock (NYSE:noir): 4.39 million shares or 5.76% ownership.
  3. RA Capital Management: 2.09 million shares or 2.75% ownership.
  4. State Street (NYSE:STT): 1.89 million shares or 2.49% ownership.
  5. International Susquehanna Group: 1.26 million shares or 1.66% ownership.

At the date of publication, Eddie Pan held (neither directly nor indirectly) any position in the securities mentioned in this article. The opinions expressed in this article are those of the author, subject to InvestorPlace.com Publication guidelines.

Comments are closed.